Macrogenics (MGNX) EPS (Weighted Average and Diluted) (2012 - 2026)
Macrogenics (MGNX) reported EPS (Weighted Average and Diluted) of -$0.58 for Q1 2026, up 10.77% year-over-year from -$0.52 in Q1 2025, and down 163.64% quarter-over-quarter from -$0.22 in Q4 2025.
Macrogenics (MGNX) EPS (Weighted Average and Diluted) (2012 - 2026) Analysis & Trends
Macrogenics (MGNX) has 14 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.58 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.58, up 10.77% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.1 (down 23.6% YoY), and the FY2025 annual result was -$1.18, down 10.28% from the prior year.
- EPS (Weighted Average and Diluted) slipped to -$0.58 in Q1 2026 per MGNX's latest filing, from -$0.22 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $0.92 in Q2 2023 and troughed at -$1.08 in Q1 2022.
- A 5-year average of -$0.29 and a median of -$0.57 in 2025 frame the typical range for EPS (Weighted Average and Diluted).
- On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 237.31% in 2023 and fell as far as 457.14% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.21 in 2022, then plunged by 457.14% to -$0.75 in 2023, then surged by 66.67% to -$0.25 in 2024, then advanced by 12.0% to -$0.22 in 2025, then plunged by 163.64% to -$0.58 in 2026.
- Business Quant data shows MGNX's EPS (Weighted Average and Diluted) at -$0.58 in Q1 2026, -$0.22 in Q4 2025, and $0.27 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Macrogenics | 260.14 Mn | 193.63 Mn | - | -0.58 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.58 |
| Dec 31, 2025 | -0.22 |
| Sep 30, 2025 | 0.27 |
| Jun 30, 2025 | -0.57 |
| Mar 31, 2025 | -0.65 |
| Dec 31, 2024 | -0.25 |
| Sep 30, 2024 | 0.90 |
| Jun 30, 2024 | -0.89 |
| Mar 31, 2024 | -0.84 |
| Dec 31, 2023 | -0.75 |
| Sep 30, 2023 | 0.28 |
| Jun 30, 2023 | 0.92 |
| Mar 31, 2023 | -0.61 |
| Dec 31, 2022 | 0.21 |
| Sep 30, 2022 | -0.40 |
| Jun 30, 2022 | -0.67 |
| Mar 31, 2022 | -1.08 |
| Dec 31, 2021 | -0.95 |
| Sep 30, 2021 | -0.86 |
| Jun 30, 2021 | -0.66 |